Dept. of Biotechnology and Life Sciences (DBSV) and Neuroscience Center, University of Insubria, Busto Arsizio, Italy.
Dept. of Biotechnology and Life Sciences (DBSV) and Neuroscience Center, University of Insubria, Busto Arsizio, Italy.
Pharmacol Ther. 2021 Oct;226:107878. doi: 10.1016/j.pharmthera.2021.107878. Epub 2021 Apr 22.
Recent years have seen a renewed interest on the possible therapeutic exploitations of specific cannabinoids derived from the Cannabis sativa plant. Thus far, the most studied non-psychotomimetic cannabinoid is cannabidiol (CBD), which has shown promising therapeutic potential for relieving a variety of neurological diseases. However, also its propyl analogue, cannabidivarin (CBDV), has recently gained much attention as a potential therapeutic agent for the management of disabling neurological conditions. This review aims at providing a comprehensive and updated overview of the available animal and human data, which have investigated the possible therapeutic potential of CBDV for the management of epilepsy and autism spectrum disorder.
近年来，人们对从大麻植物中提取的特定大麻素的潜在治疗用途重新产生了兴趣。到目前为止，研究最多的非致幻大麻素是大麻二酚（CBD），它在缓解各种神经疾病方面显示出了有希望的治疗潜力。然而，其丙基类似物大麻色烯（CBDV）最近也作为一种治疗神经障碍的潜在治疗药物引起了广泛关注。这篇综述旨在提供一个全面和最新的概述，介绍了现有的动物和人体数据，这些数据研究了 CBDV 对癫痫和自闭症谱系障碍的管理的可能治疗潜力。
